Загрузка...
Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib...
Сохранить в:
| Опубликовано в: : | Clin Case Rep |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5224778/ https://ncbi.nlm.nih.gov/pubmed/28096995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.749 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|